| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | Cost Comparison Standard |
| ID number | 6337 |
Provisional Schedule
| Expected publication | 27 November 2024 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | AstraZeneca (eplontersen) |
| Others | National Amyloidosis Centre, UCL |
| Department of Health and Social Care | |
| NHS England | |
| Patient carer groups | Gene People |
| UK ATTR Amyloidosis Patients Association | |
| Professional groups | Association of British Neurologists |
| Royal College of Physicians | |
| Comparator companies | Alnylam (patisiran, vutrisiran) |
| Akcea Therapeutics (inotersen) - not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 October 2024 - 12 November 2024 | Final draft guidance |
| 25 January 2024 | Invitation to participate |
| 21 November 2023 - 19 December 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6337 |
| 10 October 2023 | In progress. DHSC referral received |
| 29 August 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual